Bristol-Myers reports renal transplant results

Bristol-Myers Squibb Co. (NYSE:BMY) reported data from two single-blind, cyclosporine-controlled Phase III trials of belatacept ( LEA29Y) to prevent renal transplant rejection. The more intensive regimen of belatacept met the co-primary endpoints of composite patient/graft survival and composite renal function in both trials. The less intensive regimen missed the co-primary endpoint of composite renal function in one of the trials. ...